Sign the Obesity Action Coalition’s Petition to the FDA Today
By Joe Nadglowski, OAC President and CEO
As patients, many of you are aware of the never-ending battle of fighting the disease of obesity. Whether you’ve chosen weight-loss surgery, medically managed weight-loss or a commercial diet plan, the most important thing was that you had a choice. Obesity is a disease that requires not one, but many treatment options. In the coming weeks/months, the Food and Drug Administration (FDA) will be making critical decisions regarding three new drug applications for the treatment of obesity. It is imperative that these decisions are made by the FDA with an open-mind and balanced understanding.
To ensure the FDA’s review of these potentially life-saving medications is fair and balanced, we are asking you to join with the Obesity Action Coalition (OAC), and its more than 18,000 members, by signing onto the OAC’s petition to the FDA asking them to utilize a balanced approval process in evaluating new and promising medications, to be used in conjunction with diet and exercise, to help treat Americans affected by obesity.
Obesity affects nearly every organ system in the body and is often the cause of conditions such as diabetes, heart disease, pulmonary disease and multiple cancers. While many treatments have been developed and approved to address the many obesity-related conditions, the same is not true regarding obesity itself. In addition, more than one-third of Americans are affected by obesity leading to nearly $150 billion dollars in excess medical costs, and much more in personal costs.
The fact of the matter is that there are relatively few treatment options available for those impacted by obesity even though obesity is an epidemic in our country. Should the FDA fail to approve any of these three new obesity medications, we believe that will clearly indicate that the FDA has chosen a double standard for evaluating and approving treatment options for this disease. Such an outcome will leave even fewer treatment options for those who struggle with obesity and will likely further discourage any research and development in the area of obesity ever again.